RxDoctor Payments Data

Jerilyn Farmer, NP

Family · Pascagoula, MSNPI 1366749152

Payments from drug & device makers

$4,901in general payments, 2019–2025

Across 270 payments — averaging $18.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$857
  • Merck$723
  • Johnson & Johnson$464
  • Sanofi-aventis U.S. LLC$281
  • AstraZeneca$265
  • E.r. Squibb & Sons, L.L.C.$242
  • plus $2K from 28 others

What the payments were for

  • Food & beverage$4,66395%
  • Other$2385%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,901 in reported general payments places this provider in the 90th percentile of 3,007 family providers in Mississippi.

See all family providers in Mississippi

Medicare billing

Part B allowed, 2024
$67,970
Medicare patients
417
Services billed
960

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban154$158,105
JardianceEmpagliflozin78$92,158
XareltoRivaroxaban81$79,657
EntrestoSacubitril/Valsartan54$51,829
Repatha SureclickEvolocumab31$29,278
BrilintaTicagrelor33$14,052
Repatha SyringeEvolocumab12$9,623
Prasugrel Hcl39$6,259
Ezetimibe197$3,839
Propafenone Hcl ErPropafenone Hcl18$3,746
Metoprolol Succinate272$3,617
Nebivolol Hcl47$2,859
Ranolazine ErRanolazine25$2,501
Rosuvastatin Calcium206$2,427
Potassium Chloride102$2,263

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$220$158,105154 claims
Boehringer IngelheimJardiance$214$92,15878 claims
Johnson & JohnsonXarelto$464$79,65781 claims
NovartisEntresto$857$51,82954 claims
AstraZenecaBrilinta$265$14,05233 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,007 family providers in Mississippi.

Other family in Pascagoula

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →